Symbols / CRDF
CRDF Chart
About
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 105.08M |
| Enterprise Value | 45.50M | Income | -50.45M | Sales | 501.00K |
| Book/sh | 0.73 | Cash/sh | 0.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 32 | IPO | — |
| P/E | — | Forward P/E | -2.05 | PEG | — |
| P/S | 209.75 | P/B | 2.15 | P/C | — |
| EV/EBITDA | -0.85 | EV/Sales | 90.82 | Quick Ratio | 4.14 |
| Current Ratio | 4.20 | Debt/Eq | 2.07 | LT Debt/Eq | — |
| EPS (ttm) | -0.79 | EPS next Y | -0.76 | EPS Growth | — |
| Revenue Growth | -27.30% | Earnings | 2026-02-26 | ROA | -52.99% |
| ROE | -102.71% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -99.78% | Profit Margin | 0.00% | Shs Outstand | 67.36M |
| Shs Float | 65.70M | Short Float | 26.19% | Short Ratio | 9.95 |
| Short Interest | — | 52W High | 4.99 | 52W Low | 1.48 |
| Beta | 1.34 | Avg Volume | 1.25M | Volume | 436.69K |
| Target Price | $10.25 | Recom | Strong_buy | Prev Close | $1.60 |
| Price | $1.56 | Change | -2.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.25
Mean price target
2. Current target
$1.56
Latest analyst target
3. DCF / Fair value
$-6.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.56
Low
$2.50
High
$19.00
Mean
$10.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-07-08 | init | Ladenburg Thalmann | — → Buy | $19 |
| 2025-06-24 | init | Jefferies | — → Hold | $4 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-02-28 | main | HC Wainwright & Co. | Buy → Buy | $17 |
| 2024-12-13 | main | Piper Sandler | Overweight → Overweight | $10 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-09-06 | init | Craig-Hallum | — → Buy | $8 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-03-06 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-03-01 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2023-08-11 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-08 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-05-09 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2023-03-29 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2023-03-07 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2022-09-16 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2022-09-13 | main | Piper Sandler | — → Overweight | $5 |
| 2022-08-29 | main | Baird | — → Outperform | $6 |
- Cardiff Oncology down after leadership shakeup (CRDF:NASDAQ) - Seeking Alpha ue, 27 Jan 2026 08
- Cancer biotech Cardiff Oncology swaps leaders as key drug nears late-stage tests - Stock Titan ue, 27 Jan 2026 08
- Why CRDF stock is trending among retail traders - Trade Risk Assessment & Capital Efficiency Focused Strategies - mfd.ru ue, 17 Feb 2026 11
- Cardiff Oncology stock tumbles after Phase 2 trial data update By Investing.com - Investing.com Nigeria ue, 27 Jan 2026 08
- Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most - Yahoo Finance Wed, 10 Dec 2025 08
- Would You Still Hold Cardiff Oncology Stock If It Fell 30%? - Trefis Sat, 20 Dec 2025 08
- Painful week for individual investors invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) after 11% drop, institutions also suffered losses - simplywall.st hu, 20 Nov 2025 08
- Cardiff Oncology (CRDF) Shares Plunge After Executive Departures and Trial Update - GuruFocus ue, 27 Jan 2026 08
- $CRDF stock is up 5% today. Here's what we see in our data. - Quiver Quantitative Fri, 01 Aug 2025 07
- Why Did Cardiff Oncology Stock Plunge On Tuesday? - Cardiff Oncology (NASDAQ:CRDF) - Benzinga Wed, 28 Jan 2026 08
- Cardiff Oncology: Preparing For A Defining 2026 - Seeking Alpha Sat, 25 Oct 2025 07
- Colorectal trial: 72.2% response with Cardiff Oncology's onvansertib combo - Stock Titan ue, 27 Jan 2026 08
- Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance ue, 29 Jul 2025 07
- Cardiff Oncology (CRDF) Stock Drop Presents New Investment Oppor - GuruFocus Wed, 28 Jan 2026 08
- Cardiff Oncology Reports Positive Phase 2 Trial Data for Onvansertib in RAS-Mutated Metastatic Colorectal Cancer and Third Quarter Financial Results - Quiver Quantitative hu, 06 Nov 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|
| 0 | 261 | — | — | ERLANDER MARK | Officer | — | 2020-01-02 00:00:00 | D |
| 1 | 1250 | — | — | ERLANDER MARK | Officer | — | 2020-01-01 00:00:00 | D |
| 2 | 1250 | — | — | ERLANDER MARK | Officer | — | 2019-10-01 00:00:00 | D |
| 3 | 1250 | — | — | ERLANDER MARK | Officer | — | 2019-07-01 00:00:00 | D |
| 4 | 1250 | — | — | ERLANDER MARK | Officer | — | 2019-04-01 00:00:00 | D |
| 5 | 1563 | — | — | ERLANDER MARK | Officer | — | 2019-01-02 00:00:00 | D |
| 6 | 7500 | — | — | ERLANDER MARK | Officer | — | 2019-01-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -48.25M | -45.01M | -39.67M | -28.69M |
| TotalUnusualItems | 285.00K | |||
| TotalUnusualItemsExcludingGoodwill | 285.00K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -45.43M | -41.44M | -38.70M | -28.29M |
| ReconciledDepreciation | 404.00K | 398.00K | 236.00K | 451.00K |
| EBITDA | -48.25M | -45.01M | -39.67M | -28.40M |
| EBIT | -48.65M | -45.41M | -39.90M | -28.86M |
| NetInterestIncome | 3.26M | 4.07M | 1.58M | 264.00K |
| InterestExpense | 0.00 | |||
| InterestIncome | 3.26M | 4.07M | 1.58M | 264.00K |
| NormalizedIncome | -45.43M | -41.44M | -38.70M | -28.58M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -45.43M | -41.44M | -38.70M | -28.29M |
| TotalExpenses | 49.33M | 45.90M | 40.29M | 29.21M |
| TotalOperatingIncomeAsReported | -48.65M | -45.41M | -39.90M | -28.86M |
| DilutedAverageShares | 47.65M | 44.68M | 43.60M | 39.03M |
| BasicAverageShares | 47.65M | 44.68M | 43.60M | 39.03M |
| DilutedEPS | -0.95 | -0.93 | -0.89 | -0.73 |
| BasicEPS | -0.95 | -0.93 | -0.89 | -0.73 |
| DilutedNIAvailtoComStockholders | -45.45M | -41.47M | -38.73M | -28.32M |
| NetIncomeCommonStockholders | -45.45M | -41.47M | -38.73M | -28.32M |
| PreferredStockDividends | 24.00K | 24.00K | 24.00K | 24.00K |
| NetIncome | -45.43M | -41.44M | -38.70M | -28.29M |
| NetIncomeIncludingNoncontrollingInterests | -45.43M | -41.44M | -38.70M | -28.29M |
| NetIncomeContinuousOperations | -45.43M | -41.44M | -38.70M | -28.29M |
| PretaxIncome | -45.43M | -41.44M | -38.70M | -28.29M |
| OtherIncomeExpense | -39.00K | -98.00K | -383.00K | 300.00K |
| OtherNonOperatingIncomeExpenses | -39.00K | -98.00K | -383.00K | 15.00K |
| GainOnSaleOfSecurity | 285.00K | |||
| NetNonOperatingInterestIncomeExpense | 3.26M | 4.07M | 1.58M | 264.00K |
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | 3.26M | 4.07M | 1.58M | 264.00K |
| OperatingIncome | -48.65M | -45.41M | -39.90M | -28.86M |
| OperatingExpense | 49.33M | 45.90M | 40.29M | 29.21M |
| ResearchAndDevelopment | 36.85M | 32.86M | 27.11M | 17.38M |
| SellingGeneralAndAdministration | 12.48M | 13.04M | 13.18M | 11.84M |
| GeneralAndAdministrativeExpense | 12.48M | 13.04M | 13.18M | 11.84M |
| OtherGandA | 6.10M | 6.28M | 6.83M | 6.60M |
| SalariesAndWages | 6.39M | 6.76M | 6.36M | 5.23M |
| TotalRevenue | 683.00K | 488.00K | 386.00K | 359.00K |
| OperatingRevenue | 683.00K | 488.00K | 386.00K | 359.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 66.52M | 44.68M | 44.68M | 41.96M |
| ShareIssued | 66.52M | 44.68M | 44.68M | 41.96M |
| TotalDebt | 1.52M | 2.15M | 2.71M | 3.12M |
| TangibleBookValue | 82.95M | 69.74M | 106.34M | 140.42M |
| InvestedCapital | 82.95M | 69.74M | 106.34M | 140.42M |
| WorkingCapital | 81.63M | 66.97M | 103.48M | 139.57M |
| NetTangibleAssets | 82.95M | 69.74M | 106.34M | 140.42M |
| CapitalLeaseObligations | 1.52M | 2.15M | 2.71M | 3.12M |
| CommonStockEquity | 82.95M | 69.74M | 106.34M | 140.42M |
| PreferredStockEquity | 1.00K | |||
| TotalCapitalization | 82.95M | 69.74M | 106.34M | 140.42M |
| TotalEquityGrossMinorityInterest | 82.95M | 69.74M | 106.34M | 140.42M |
| StockholdersEquity | 82.95M | 69.74M | 106.34M | 140.42M |
| OtherEquityInterest | -139.00K | |||
| GainsLossesNotAffectingRetainedEarnings | 34.00K | -67.00K | -395.00K | -142.00K |
| OtherEquityAdjustments | 34.00K | -67.00K | -395.00K | -142.00K |
| RetainedEarnings | -384.18M | -339.54M | -298.10M | -259.81M |
| AdditionalPaidInCapital | 467.09M | 409.34M | 404.83M | 400.50M |
| CapitalStock | 7.00K | 4.00K | 4.00K | 5.00K |
| CommonStock | 7.00K | 4.00K | 4.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 1.00K |
| TotalLiabilitiesNetMinorityInterest | 14.24M | 11.90M | 9.85M | 9.13M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 813.00K | 1.46M | 2.04M | 2.57M |
| DerivativeProductLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 813.00K | 1.46M | 2.04M | 2.57M |
| LongTermCapitalLeaseObligation | 813.00K | 1.46M | 2.04M | 2.57M |
| CurrentLiabilities | 13.43M | 10.44M | 7.81M | 6.56M |
| OtherCurrentLiabilities | 42.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 710.00K | 691.00K | 675.00K | 551.00K |
| CurrentCapitalLeaseObligation | 710.00K | 691.00K | 675.00K | 551.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.75M | 2.74M | 1.85M | 1.44M |
| PayablesAndAccruedExpenses | 9.97M | 7.01M | 5.28M | 4.53M |
| CurrentAccruedExpenses | 5.15M | 5.05M | 3.33M | 2.68M |
| Payables | 4.82M | 1.97M | 1.96M | 1.85M |
| DividendsPayable | 0.00 | 414.00K | ||
| AccountsPayable | 4.82M | 1.97M | 1.96M | 1.44M |
| TotalAssets | 97.19M | 81.64M | 116.19M | 149.54M |
| TotalNonCurrentAssets | 2.14M | 4.22M | 4.91M | 3.42M |
| OtherNonCurrentAssets | 69.00K | 1.28M | 1.39M | 239.00K |
| NetPPE | 2.07M | 2.95M | 3.52M | 3.18M |
| AccumulatedDepreciation | -4.14M | -3.75M | -3.41M | -3.44M |
| GrossPPE | 6.20M | 6.70M | 6.93M | 6.62M |
| Leases | 2.57M | 2.57M | 2.56M | 1.96M |
| OtherProperties | 2.58M | 3.06M | 3.31M | 3.70M |
| MachineryFurnitureEquipment | 1.05M | 1.07M | 1.07M | 955.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 95.05M | 77.41M | 111.28M | 146.13M |
| OtherCurrentAssets | 2.54M | 2.30M | 5.25M | 4.77M |
| PrepaidAssets | 4.77M | |||
| Receivables | 773.00K | 288.00K | 771.00K | 535.00K |
| AccountsReceivable | 773.00K | 288.00K | 771.00K | 535.00K |
| CashCashEquivalentsAndShortTermInvestments | 91.75M | 74.82M | 105.27M | 140.82M |
| OtherShortTermInvestments | 40.28M | 53.17M | 88.92M | 128.88M |
| CashAndCashEquivalents | 51.47M | 21.66M | 16.35M | 11.94M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -37.77M | -31.47M | -34.83M | -23.25M |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 53.41M | 0.00 | 0.00 | 34.19M |
| CapitalExpenditure | -80.00K | -582.00K | -1.01M | -205.00K |
| IncomeTaxPaidSupplementalData | 1.00K | 2.00K | 1.00K | |
| EndCashPosition | 51.47M | 21.66M | 16.35M | 11.94M |
| BeginningCashPosition | 21.66M | 16.35M | 11.94M | 130.98M |
| ChangesInCash | 29.82M | 5.31M | 4.40M | -119.04M |
| FinancingCashFlow | 53.78M | 0.00 | 75.00K | 35.45M |
| CashFlowFromContinuingFinancingActivities | 53.78M | 0.00 | 75.00K | 35.45M |
| ProceedsFromStockOptionExercised | 373.00K | 0.00 | 75.00K | 1.26M |
| NetCommonStockIssuance | 53.41M | 0.00 | 0.00 | 34.19M |
| CommonStockIssuance | 53.41M | 0.00 | 0.00 | 34.19M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 13.73M | 36.20M | 38.15M | -131.45M |
| CashFlowFromContinuingInvestingActivities | 13.73M | 36.20M | 38.15M | -131.45M |
| NetOtherInvestingChanges | 114.00K | |||
| NetInvestmentPurchaseAndSale | 13.81M | 36.78M | 39.04M | -131.24M |
| SaleOfInvestment | 37.37M | 106.86M | 130.27M | 43.14M |
| PurchaseOfInvestment | -23.56M | -70.08M | -91.23M | -174.38M |
| CapitalExpenditureReported | -80.00K | -582.00K | -1.01M | -205.00K |
| OperatingCashFlow | -37.69M | -30.89M | -33.82M | -23.04M |
| CashFlowFromContinuingOperatingActivities | -37.69M | -30.89M | -33.82M | -23.04M |
| ChangeInWorkingCapital | 3.17M | 6.57M | -380.00K | -1.79M |
| ChangeInOtherCurrentLiabilities | -626.00K | -566.00K | -446.00K | -967.00K |
| ChangeInOtherCurrentAssets | 1.75M | 651.00K | -603.00K | 773.00K |
| ChangeInPayablesAndAccruedExpense | 2.98M | 2.83M | 1.35M | 719.00K |
| ChangeInPrepaidAssets | -452.00K | 3.17M | -443.00K | -2.10M |
| ChangeInReceivables | -484.00K | 483.00K | -236.00K | -215.00K |
| OtherNonCashItems | 139.00K | 2.03M | ||
| StockBasedCompensation | 4.76M | 4.51M | 4.26M | 3.23M |
| AssetImpairmentCharge | 0.00 | |||
| AmortizationOfSecurities | -598.00K | -921.00K | 632.00K | 1.61M |
| DepreciationAmortizationDepletion | 404.00K | 398.00K | 236.00K | 451.00K |
| DepreciationAndAmortization | 404.00K | 398.00K | 236.00K | 451.00K |
| Depreciation | 404.00K | 398.00K | 236.00K | 451.00K |
| OperatingGainsLosses | 1.00K | -284.00K | ||
| GainLossOnInvestmentSecurities | -285.00K | |||
| NetIncomeFromContinuingOperations | -45.43M | -41.44M | -38.70M | -28.29M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRDF
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|